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Tolerogenic vaccines represent a new class of vaccine designed to re-estab-
lish immunological tolerance, restore 
immune homeostasis, and thereby 
reverse autoimmune disease. Tolerogenic 
vaccines induce long-term, antigen-
specific, inhibitory memory that blocks 
pathogenic T cell responses via loss of 
effector T cells and gain of regulatory T 
cell function. Substantial advances have 
been realized in the generation of tolero-
genic vaccines that inhibit experimental 
autoimmune encephalomyelitis in a pre-
clinical setting, and these vaccines may 
be a prequel of the tolerogenic vaccines 
that may have therapeutic benefit in 
Multiple Sclerosis. The purpose here is 
to provide a snapshot of the current con-
cepts and future prospects of tolerogenic 
vaccination for Multiple Sclerosis, along 
with the central challenges to clinical 
application.
Immunogenic and Tolerogenic 
Vaccines: A Primer
The classic immunogenic vaccines rep-
resent one of the most successful and 
cost-effective interventions in the history 
of medicine. The field of vaccination is 
now rapidly expanding to encompass a 
new class of vaccines (i.e., the tolerogenic 
vaccines) that induce immunological 
tolerance to alleviate the inflammatory 
autoimmune diseases as well as other 
inflammatory diseases of metabolism, 
neurodegeneration, allergic hypersen-
sitivity, and transplantation rejection. 
Immunogenic and tolerogenic vaccines 
differ in many fundamentals. First, immu-
nogenic vaccines have had unparalleled 
clinical success, including the elimination 
of smallpox and the near-eradication of 
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polio and are credited with saving untold 
millions of lives. Conversely, tolerogenic 
vaccines are largely experimental and 
are currently pursued in pre-clinical set-
tings or in early-phase clinical trials and 
are studied based on their future poten-
tial rather than their clinical actuality. 
Second, classic immunogenic vaccination 
is based on the activation, expansion, and 
differentiation of memory T cell clones 
specific for particular infectious antigens 
that then provide rapid immunity to any 
re-exposure of that infectious pathogen. 
Likewise, tolerogenic vaccines are contin-
gent upon the generation of long-lasting 
memory, but this memory is due to the 
activation, expansion, and differentiation 
of antigen-specific regulatory T cells that 
mediate antigen-specific inhibitory activ-
ity by mechanisms of active, dominant 
tolerance. Tolerogenic vaccines also elicit 
“passive” tolerance marked by immuno-
logical anergy and the functional and/ 
or physical elimination of pathogenic T 
cell clones and the consequent creation 
of a “hole in the repertoire” marked by 
the passive lack of T cell reactivity to a 
given self antigen. Third, immunogenic 
vaccines usually require strong immu-
nological adjuvants to prime the initial 
immunization via stimulatory interactions 
with innate immune receptor systems that 
recognize “pattern-associated molecu-
lar patterns” or PAMPs that are shared 
among large classes of infectious patho-
gens. Activation of receptor systems such 
as the toll-like receptors (TLR) or NOD-
like receptors (NLR) on mononuclear 
phagocytes triggers immunogenic presen-
tation of the associated antigens on MHC 
class II molecules together with strong co-
stimulation to elicit activation and differ-
entiation of naïve T cells as the founding 
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progressive autoimmune course indepen-
dent of any recurring infectious disease 
trigger.
These considerations underlie key 
unanswered questions that will shape the 
future of tolerogenic vaccine research in 
MS. Can effective tolerogenic vaccination 
be accomplished by targeting a limited 
number of myelin epitopes or will such 
vaccines need to cover a wide diversity of 
antigenic targets? A parallel question is 
the degree of patient-to-patient variabil-
ity of the antigenic specificities that drive 
MS. The potential answers to these ques-
tions cover a wide range of possibilities, 
including the possibility of a common 
MS vaccine bearing a limited number of 
dominant myelin epitopes that will be 
effective for most MS patients. On the 
opposite side of the spectrum, MS vaccines 
may need to be individualized vaccines 
that cover numerous and highly diverse 
myelin epitopes based on unique sets of 
reactivities for each patient. This range 
of possibilities addresses important issues 
of feasibility and experimental approach 
in the design and testing of experimen-
tal vaccines. Whether pauci-clonal or 
broadly polyclonal T cells mediate MS 
is a critical consideration for tolerogenic 
vaccine development. If MS is mediated 
by T cells of restricted clonotypic diver-
sity and little patient-to-patient variabil-
ity in myelin specificities, then standard 
tolerogenic vaccine strategies may suffice 
for many MS patients. However, if MS 
is mediated by an ever-broadening rep-
ertoire of autoreactive T cells with sub-
stantial inter-patient variation, then new 
vaccine strategies will be needed to match 
therapy with a dynamically changing 
landscape of T cell autoreactivities. If the 
latter scenario is the case, early diagnosis 
and intervention will be key consider-
ations for effective tolerogenic vaccina-
tion. New technologies will be needed 
to identify clonally-expanded, “smoking-
gun” myelin-reactive clones. Because one 
will not want to introduce vaccines that 
are off-target and not relevant to a given 
patient, vaccines will need to have a mod-
ular design so that epitopes can be readily 
added or subtracted from a vaccine cock-
tail to tailor the therapy to the reactivi-
ties of particular patients. Alternatively, 
new vaccine strategies could be developed 
The Vaccine Target(s) in MS
“Molecular mimicry” is the leading model 
to explain the etiology of MS.30-33 This 
model predicts that chronic or recurring 
infectious agents are the etiological insti-
gators of MS. The prediction is that such 
etiological agents have overlapping and 
partially shared antigenic epitopes with 
major myelin proteins. In the context of 
chronic or recurrent infection, these infec-
tious pathogens are postulated to stimu-
late strong T cell-mediated immunity 
against the foreign “mimicry” epitope(s). 
After clonal expansion and differentiation 
into memory/ effector subsets, through 
mechanisms of immune surveillance, 
these crossreactive T cell clones are postu-
lated to find and react to the endogenous 
crossreactive myelin epitopes in the CNS 
to mediate MS (Fig. 1). These infectious 
agents, upon repeated re-emergence from 
latency, may drive relapses of MS and the 
chronic relapsing-remitting disease course 
of MS.
The “molecular mimicry” model gives 
rise to a range of possibilities in regard to 
the nature of the autoantigens that drive 
the disease process. The key crossreactivi-
ties may be chance occurrences, and only 
one or two crossreactive epitopes may be 
responsible for initiation of the MS disease 
process. Conversely, the molecular mim-
icry may be driven by directed evolution-
ary pressures by which the infectious agent 
has adapted to a specialized infectious 
niche. For example, the infectious agent 
may be evolutionarily adapted to persist 
in an organ such as the CNS by bearing 
camouflage comprised of many epitopes 
that resemble and are crossreactive with 
the local host tissue. Mechanisms of “epi-
tope spreading” may further complicate 
vaccine development.34-36 “Epitope spread-
ing” refers to a mechanism by which the 
instigating myelin-reactive clones drive 
CNS inflammation and recruit new, dis-
tinct clonotypes of naïve myelin-reactive 
clones into the CNS, where the latter 
clones differentiate into memory/ effec-
tor T cells upon recognition of a distinct 
set of CNS antigens to cause additional 
neurologic damage. Thus, over time, the 
anti-myelin T cell repertoire may broaden 
and diversify, and may acquire sufficient 
clonotypic diversity to sustain a chronic or 
event in the adaptive immune response. In 
contrast, tolerogenic vaccines are designed 
to have minimal adjuvant activity so that 
the vaccine antigens are recognized in 
non-activated, non-inflammatory envi-
ronments that favor self-tolerance. Fourth, 
immunogenic vaccines in current prac-
tice are largely based on the generation 
of humoral immunity with an emphasis 
on disease prevention rather than therapy 
of pre-established disease. In contrast, 
tolerogenic vaccines must counter ongoing 
pathogenic T cell-mediated memory, and 
the emphasis is on therapy of established 
chronic disease rather than prevention of 
future disease.
Tolerogenic Vaccination for  
Multiple Sclerosis (MS): The  
Targets, the Challenges, the  
Strategies and the Future
The use of experimental autoimmune 
encephalomyelitis (EAE) as the proto-
typic model of MS has fundamentally 
shaped the core expectations and predic-
tions of MS,1-9 including the presumption 
that MS is an inflammatory autoimmune 
disease mediated by pathogenic CD4+ 
T-helper cells specific for myelin proteins 
of the central nervous system (CNS) 
such as myelin basic protein (MBP), 
proteolipid protein (PLP), and myelin 
oligodendrocyte glycoprotein (MOG). 
Myelin-specific CD4+ T cells may also 
recruit additional effector subsets with 
shared anti-myelin protein reactivity such 
as B cells and CD8+ T cells to partake in 
the autoimmune destruction of the CNS 
target tissue.10-16 The purpose here is not 
to debate the merits of the EAE model 
but rather to discuss the essential consid-
erations inherent to this model for devel-
oping tolerogenic vaccines for MS. Many 
tolerogenic vaccine platforms have been 
tested for development in EAE and MS.17-
29 These vaccine strategies for MS require 
consideration on three levels, including; 
(a) the identity and diversity of target 
CNS antigens, particularly the peptide 
epitopes of major myelin protein antigens, 
(b) the inherent efficiency by which these 
clones recognize their target self antigens, 
and (c) the qualitative activity of the vac-
cine in the midst of a pro-inflammatory 
local environment.
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considered sufficient to drive activation 
and the differentiation of naïve T cells 
into memory or effector T cells. In con-
trast, the less efficient myelin epitopes are 
postulated to lack the capacity to drive 
differentiation of naïve T cells. Thus, the 
foreign mimicry epitopes may provide 
the critical “activation energy” to initi-
ate autoimmune responses. The relevant 
myelin-reactive clones, even after achiev-
ing effector status, would continue to rec-
ognize endogenous myelin epitopes with 
low efficiency. Once the foreign mimicry 
antigen caused effector cell formation, the 
low efficiency recognition of myelin by 
effector/ memory T cells is postulated to 
be sufficient to elicit tissue damage39,41 but 
may be insufficient to sustain the immune 
response. Indeed, the low affinity recogni-
tion of myelin epitopes may be inherently 
tolerogenic.
variation would be a compelling rationale 
to test novel modular vaccine designs or 
approaches based on full-length myelin 
proteins.
Antigen Recognition Efficiencies
The second consideration is the efficiency 
by which the myelin-reactive T cells rec-
ognize the relevant cross-reactive foreign 
and self antigens (Fig. 1). The general 
consideration is that the cross-reactive clo-
notypes recognize the foreign “mimicry” 
epitopes of the infectious agent with quali-
tatively superior efficiency compared with 
self myelin epitopes.37-39 The differential 
reactivity is simply a consequence of self 
tolerance induction during development 
of the immune system, which precludes 
clones with strong reactivity to self.40 The 
strength of foreign antigen recognition is 
to include full-length myelin proteins, 
including hydrophobic transmembrane 
domains. Most tolerogenic vaccine strat-
egies have focused on defined encephali-
togenic epitopes that are hydrophilic for 
practical reasons of solubility. Vaccines 
that include full length myelin proteins 
would need to be produced by technolo-
gies that do not result in protein aggrega-
tion, because aggregated proteins would 
likely cause the adverse side-effect and 
the strongly contraindicated production 
of anti-myelin autoantibodies. This spec-
trum of possibilities will shape the future 
development of optimal tolerogenic vac-
cines. The assumption of a common dom-
inant MS antigen can serve as the basis 
to test experimental strategies designed to 
maximize the efficacy of tolerogenic vac-
cines. The assumption of myriads of vac-
cine targets with substantial inter-patient 
Figure 1. Hypothetical model of action for tolerogenic vaccines. natural homeostatic mechanisms of self tolerance are noted in blue. endogenous 
myelin autoantigens and other crossreactive self antigens shape development of the t cell repertoire so that conventional t cells recognize “self” 
with an efficiency that is below the threshold necessary to drive differentiation of memory/ effector subsets. endogenous myelin autoantigens also 
promote the differentiation of regulatory t cell subsets. together, the two mechanisms (low efficacy recognition of self by conventional t cells and 
active, dominant inhibitory action of regulatory t cells) prevent differentiation of myelin-specific t cells into memory or effector subsets and thereby 
prevent autoimmune disease. the mechanism of “molecular mimicry” is represented in red. a crossreactive foreign antigen from a recurrent or chronic 
infectious pathogen drives crossreactive clones with sufficiently high efficacy to override homeostatic regulatory mechanisms. these high efficiency 
foreign “mimic” antigens drive the differentiation of myelin-crossreactive t cells into memory/ effector subsets. the potential consequence is the 
initiation of a potentially self-sustaining autoimmune response against myelin and induction of MS. a potential beneficial effect is that these crossre-
active clones may eliminate or suppress the etiological infection and thereby clear the antigenic stimulus of the autoimmune disease. the proposed 
action of tolerogenic vaccines is represented in green. tolerogenic vaccines are postulated to reinforce myelin-specific regulatory t cell subsets and 
cause anergy/ apoptosis of myelin-reactive naïve and memory/ effector t cell subsets, even in the midst of an inflammatory environment. arrowheads 
represent stimulatory interactions. Spherical line-ends represent inhibitory actions.
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based on whether the vaccine is admin-
istered into a quiescent or pro-inflam-
matory environment. However, this 
idea can be challenged on theoretical 
and experimental grounds and may dif-
ferentially apply to distinct tolerogenic 
vaccine platforms. Autoreactive T cells 
circulate in normal individuals but do not 
cause autoimmunity in the vast majority 
of persons even though the host is con-
tinually subjected to infectious disease, 
injury, and various inflammatory insults. 
Regulatory networks apparently are not 
so simply co-opted by inflammatory envi-
ronments. Indeed, regulatory networks 
comprised of Foxp3+CD4+CD25+ may 
be strengthened by antigen recognition 
in the presence of B7-mediated costimu-
lation and various cytokines, particularly 
IL-2.53,54 Thus, one cannot conclude that 
the inhibitory activity of a tolerogenic vac-
cine would be preempted within a pro-
inflammatory environment. As a case in 
point, a GMCSF-NAg tolerogenic vac-
cine was administered at the same time 
and at sites immediately adjacent to the 
encephalitogenic peptide/Complete 
Freund’s Adjuvant (CFA) immunization. 
In this paradigm, GMCSF-NAg retained 
inhibitory activity and prevented EAE in 
a majority of immunized mice.18 Thus, 
the GMCSF-NAg vaccine retained inhibi-
tory activity even in the midst of a CFA-
polarized inflammatory environment. 
Thus, a critical test of a tolerogenic vac-
cine platform is the deliberate introduc-
tion of the vaccine in a proinflammatory 
environment, either administered after 
disease onset or together with adjuvants 
or other pro-inflammatory stimuli during 
encephalitogenic immunization. In this 
regard, GMCSF-NAg effectively inhib-
ited disease when delivered into the same 
lymphatic drainage at the same time as 
the encephalitogenic/CFA immunization. 
The GMCSF-NAg vaccine also inhibited 
EAE when given at disease onset, or alter-
natively, when given during established 
chronic EAE.18,42,43
The Future
A primary prediction of the EAE model of 
MS is that the study of the myelin-specific 
T cell repertoire of MS patients should 
reveal the key specificities that underlie 
the antigenic domain.43 The “self” NAg 
domains of GMCSF-NAg fusion proteins, 
by engaging developmentally established 
regulatory networks, would be predicted 
to promote tolerance. Conversely, the 
“foreign-antigen” domains of GMCSF-
antigen fusion proteins would predomi-
nantly engage a repertoire of conventional 
T cells rather than regulatory T cells 
and thereby would drive immunogenic 
responses. These predictions are consis-
tent with the experimental observations 
that GM-CSF may amplify the intrin-
sic tolerogenic or immunogenic activity 
of the antigenic domain. The inherent 
tolerogenic activity of self antigens, even 
in the midst of an ongoing autoimmune 
disease, may appear paradoxical but is a 
key element in the feasibility and potential 
success of tolerogenic vaccines.
The Environment
One of the primary concerns regarding 
tolerogenic vaccines is the possibility that 
administration of a “tolerogenic vaccine” 
to particular patients may be immuno-
genic rather tolerogenic and worsen the 
MS disease course, as may have occurred 
in clinical trials of “altered peptide ligands 
or APL”.46 Underlying this concern is the 
concept that tolerogenic vaccines have 
tolerogenic activity because these vac-
cines are administered without adjuvants 
and thus are presented to the immune 
system in a quiescent, non-activated envi-
ronment.47-52 The idea is that antigen pre-
sentation in the absence of costimulatory 
molecules and without a complement of 
proinflammatory cytokines is critical for 
inhibitory vaccine activity. However, the 
environment of the vaccine recipient will 
be difficult to control in a clinical setting 
because at least some patients will have 
inapparent infections or exposure to other 
pro-inflammatory stimuli either locally 
or systemically. If a tolerogenic vaccine is 
administered into such a pro-inflamma-
tory environment, the vaccine would per-
haps adversely worsen the disease course. 
The extent to which this issue applies to 
a tolerogenic vaccine platform represents 
a critical consideration regarding the pro-
jected success of that vaccine platform.
The notion is widely-held that a vac-
cine is either tolerogenic or immunogenic 
The myelin-specific regulatory T cell 
networks that were overridden by the 
strong foreign stimulus are thought to be 
intact and capable of restoring homeo-
stasis once the foreign mimicry has been 
cleared from the tissue (Fig. 1). These reg-
ulatory networks are most likely dominant 
in the absence of the infectious stimulus. 
The important concept is that the reper-
toires of the myelin-reactive regulatory 
T cells and the myelin-reactive conven-
tional T cells most likely share a common 
myelin reactivity (representing the normal 
mechanism of homeostasis), but the regu-
latory T cells most likely do not recognize 
the foreign mimicry antigens due to the 
absence of these foreign antigens during 
development. If regulatory T cells per 
chance did crossreact with the mimicry 
antigens, then the immune system would 
not respond to these foreign mimicry epi-
topes, and the individual would not suf-
fer from an autoimmune disease. Because 
tolerogenic vaccines contain native myelin 
epitopes, tolerogenic vaccination would 
predictably reinforce regulatory T cell 
function and the low efficiency interac-
tions that promote tolerance rather than 
immunity, even after differentiation of the 
conventional myelin-reactive T cells into 
memory and effector subsets.
As a case in point, one of the most 
profoundly tolerogenic vaccines stud-
ied by our laboratory is comprised of the 
cytokine GM-CSF fused to the major 
encephalitogenic epitopes from MBP, 
MOG, or PLP in rat and mouse models 
of EAE.18,42,43 The GMCSF-neuroantigen 
(NAg) vaccine requires covalent linkage 
of the cytokine and NAg domains for 
tolerogenic efficacy. Conversely, a substan-
tial number of studies have shown that 
GM-CSF fusions with foreign antigens act 
as immunogenic vaccines and can be used 
to augment immune responses against 
foreign antigens.44,45 Taken together, these 
studies suggest that the antigenic domain 
aside from the GM-CSF domain may bias 
the inherent activity of the vaccine. Thus, 
the self or nonself origins of the antigenic 
domain may play an important role in con-
trolling the balance between tolerance and 
immunity. An important functionality of 
the GM-CSF domain may simply involve 
targeting of the vaccine to dendritic cells 
to promote more efficient presentation of 
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verify the tolerogenic efficacy of the vac-
cine approach, and the identity of the vac-
cine NAg domain would definitively link 
that NAg specificity as a foundation of 
MS pathogenesis. Thus, clinical trials of 
tolerogenic vaccines may be a key experi-
mental venue to not only treat MS but to 
reveal the underlying pathogenesis of MS. 
Thus, over the course of the next decade, 
the hope is that tolerogenic vaccines will 
begin to reveal the “nature of the beast” 
that is MS.
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genic target in Neuromyelitis Optica, and 
the inward-rectifying KIR4.1 potassium 
channel appears to be a major target of 
the humoral immune response in many 
adult MS patients. Humoral responses 
to MOG are apparent in patients with 
Acute Disseminated Encephalomyelitis 
and pediatric MS. Human T cell antigen 
receptor chains specific for myelin peptides 
have been expressed in mice as transgenes 
together with the human MHC class II 
restriction alleles, and these transgenic 
mice show spontaneous EAE.67-69 These 
and other approaches provide compelling 
evidence that particular antigen speci-
ficities are associated with MS and related 
neurologic diseases. However, the true 
encephalitogenic drivers of MS remain 
unknown. As a key question for the future 
of the field, consideration must be given to 
those experimental approaches that might 
best reveal causal links between a given 
antigenic specificity and MS pathogenesis. 
Tolerogenic vaccines may provide the key 
to the solution. In this regard, a central 
goal of the field is to devise and test tolero-
genic vaccines as interventions in MS. A 
major step forward would be a successful 
clinical trial of an efficacious tolerogenic 
vaccine. Such an accomplishment would 
www.landesbioscience.com Human Vaccines & Immunotherapeutics 1037
52. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, 
Nussenzweig MC, Steinman RM. Efficient targeting 
of protein antigen to the dendritic cell receptor DEC-
205 in the steady state leads to antigen presentation 
on major histocompatibility complex class I products 
and peripheral CD8+ T cell tolerance. J Exp Med 
2002; 196:1627-38; PMID:12486105; http://dx.doi.
org/10.1084/jem.20021598.
53. Pletinckx K, Döhler A, Pavlovic V, Lutz MB. Role of 
dendritic cell maturity/costimulation for generation, 
homeostasis, and suppressive activity of regulatory T 
cells. Front Immunol 2011; 2:39; PMID:22566829; 
http://dx.doi.org/10.3389/fimmu.2011.00039.
54. Kornete M, Piccirillo CA. Critical co-stimulato-
ry pathways in the stability of Foxp3+ Treg cell 
homeostasis in Type I diabetes. Autoimmun Rev 
2011; 11:104-11; PMID:21875694; http://dx.doi.
org/10.1016/j.autrev.2011.08.007.
55. Elong Ngono A, Pettré S, Salou M, Bahbouhi B, 
Soulillou JP, Brouard S, et al. Frequency of circu-
lating autoreactive T cells committed to myelin 
determinants in relapsing-remitting multiple scle-
rosis patients. Clin Immunol 2012; 144:117-26; 
PMID:22717772; http://dx.doi.org/10.1016/j.
clim.2012.05.009.
56. Grau-López L, Raïch D, Ramo-Tello C, Naranjo-
Gómez M, Dàvalos A, Pujol-Borrell R, et al. Myelin 
peptides in multiple sclerosis. Autoimmun Rev 
2009; 8:650-3; PMID:19393199; http://dx.doi.
org/10.1016/j.autrev.2009.02.013.
57. Bielekova B, Sung MH, Kadom N, Simon R, 
McFarland H, Martin R. Expansion and function-
al relevance of high-avidity myelin-specific CD4+ 
T cells in multiple sclerosis. J Immunol 2004; 
172:3893-904; PMID:15004197.
58. Burns J, Bartholomew B, Lobo S. Isolation of 
myelin basic protein-specific T cells predomi-
nantly from the memory T-cell compartment in 
multiple sclerosis. Ann Neurol 1999; 45:33-9; 
PMID:9894874; http://dx.doi.org/10.1002/1531-
8249(199901)45:1<33::AID-ART7>3.0.CO;2-G.
59. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, 
June CH, Racke MK. Decreased dependence of 
myelin basic protein-reactive T cells on CD28-
mediated costimulation in multiple sclerosis patients. 
A marker of activated/memory T cells. J Clin Invest 
1998; 101:725-30; PMID:9466965; http://dx.doi.
org/10.1172/JCI1528.
60. Scholz C, Patton KT, Anderson DE, Freeman 
GJ, Hafler DA. Expansion of autoreactive T cells 
in multiple sclerosis is independent of exogenous 
B7 costimulation. J Immunol 1998; 160:1532-8; 
PMID:9570577.
61. Uccelli A, Giunti D, Salvetti M, Ristori G, Fenoglio 
D, Abbruzzese, et al. A restricted T cell response 
to myelin basic protein (MBP) is stable in mul-
tiple sclerosis (MS) patients. Clin Exp Immunol 
1998; 111:186-92; PMID:9472680; http://dx.doi.
org/10.1046/j.1365-2249.1998.00457.x.
62. Mayer MC, Meinl E. Glycoproteins as tar-
gets of autoantibodies in CNS inf lamma-
tion: MOG and more. Ther Adv Neurol Disord 
2012; 5:147-59; PMID:22590479; http://dx.doi.
org/10.1177/1756285611433772.
63. Rostasy K, Mader S, Schanda K, Huppke P, 
Gärtner J, Kraus V, et al. Anti-myelin oligodendro-
cyte glycoprotein antibodies in pediatric patients 
with optic neuritis. Arch Neurol 2012; 69:752-6; 
PMID:22371853.
64. Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck 
D, Tackenberg B, et al. Potassium channel KIR4.1 as 
an immune target in multiple sclerosis. N Engl J Med 
2012; 367:115-23; PMID:22784115; http://dx.doi.
org/10.1056/NEJMoa1110740.
65. Pröbstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, 
Magalhaes S, et al. Antibodies to MOG are transient 
in childhood acute disseminated encephalomyelitis. 
Neurology 2011; 77:580-8; PMID:21795651; http://
dx.doi.org/10.1212/WNL.0b013e318228c0b1.
39. Sabatino JJ Jr., Huang J, Zhu C, Evavold BD. 
High prevalence of low affinity peptide-MHC II 
tetramer-negative effectors during polyclonal CD4+ 
T cell responses. J Exp Med 2011; 208:81-90; 
PMID:21220453; http://dx.doi.org/10.1084/
jem.20101574.
40. Goverman JM. Immune tolerance in mul-
tiple sclerosis. Immunol Rev 2011; 241:228-40; 
PMID:21488900; http://dx.doi.org/10.1111/j.1600-
065X.2011.01016.x.
41. Sabatino JJ Jr., Rosenthal KM, Evavold BD. 
Manipulating antigenic ligand strength to selec-
tively target myelin-reactive CD4+ T cells in 
EAE. J Neuroimmune Pharmacol 2010; 5:176-88; 
PMID:19904613; http://dx.doi.org/10.1007/s11481-
009-9181-3.
42. Abbott DJ, Blanchfield JL, Martinson DA, Russell 
SC, Taslim N, Curtis AD, et al. Neuroantigen-
specific, tolerogenic vaccines: GM-CSF is a fusion 
partner that facilitates tolerance rather than immu-
nity to dominant self-epitopes of myelin in murine 
models of experimental autoimmune encepha-
lomyelitis (EAE). BMC Immunol 2011; 12:72; 
PMID:22208499; http://dx.doi.org/10.1186/1471-
2172-12-72.
43. Blanchfield JL, Mannie MD. A GMCSF-
neuroantigen fusion protein is a potent tolerogen in 
experimental autoimmune encephalomyelitis (EAE) 
that is associated with efficient targeting of neu-
roantigen to APC. J Leukoc Biol 2010; 87:509-
21; PMID:20007248; http://dx.doi.org/10.1189/
jlb.0709520.
44. Wortham C, Grinberg L, Kaslow DC, Briles DE, 
McDaniel LS, Lees A, et al. Enhanced protective 
antibody responses to PspA after intranasal or sub-
cutaneous injections of PspA genetically fused to 
granulocyte-macrophage colony-stimulating factor 
or interleukin-2. Infect Immun 1998; 66:1513-20; 
PMID:9529075.
45. Jones T, Stern A, Lin R. Potential role of granulocyte-
macrophage colony-stimulating factor as vaccine 
adjuvant. Eur J Clin Microbiol Infect Dis 1994; 
13(Suppl 2):S47-53; PMID:7875153; http://dx.doi.
org/10.1007/BF01973602.
46. Bielekova B, Goodwin B, Richert N, Cortese I, 
Kondo T, Afshar G, et al. Encephalitogenic potential 
of the myelin basic protein peptide (amino acids 
83-99) in multiple sclerosis: results of a phase II 
clinical trial with an altered peptide ligand. Nat Med 
2000; 6:1167-75; PMID:11017150; http://dx.doi.
org/10.1038/80516.
47. Amodio G, Gregori S. Dendritic cells a double-edge 
sword in autoimmune responses. Front Immunol 
2012; 3:233; PMID:22876246; http://dx.doi.
org/10.3389/fimmu.2012.00233.
48. Fukaya T, Takagi H, Taya H, Sato K. DCs in immune 
tolerance in steady-state conditions. Methods Mol 
Biol 2011; 677:113-26; PMID:20941606; http://
dx.doi.org/10.1007/978-1-60761-869-0_8.
49. Nasreen M, Waldie TM, Dixon CM, Steptoe RJ. 
Steady-state antigen-expressing dendritic cells termi-
nate CD4+ memory T-cell responses. Eur J Immunol 
2010; 40:2016-25; PMID:20405475; http://dx.doi.
org/10.1002/eji.200940085.
50. Doan T, McNally A, Thomas R, Steptoe RJ. Steady-
state dendritic cells continuously inactivate T cells 
that escape thymic negative selection. Immunol 
Cell Biol 2009; 87:615-22; PMID:19581919; http://
dx.doi.org/10.1038/icb.2009.46.
51. Fisson S, Darrasse-Jèze G, Litvinova E, Septier F, 
Klatzmann D, Liblau R, et al. Continuous activa-
tion of autoreactive CD4+ CD25+ regulatory T 
cells in the steady state. J Exp Med 2003; 198:737-
46; PMID:12939344; http://dx.doi.org/10.1084/
jem.20030686.
24. Stern JN, Keskin DB, Kato Z, Waldner H, 
Schallenberg S, Anderson A, et al. Promoting toler-
ance to proteolipid protein-induced experimental 
autoimmune encephalomyelitis through targeting 
dendritic cells. Proc Natl Acad Sci U S A 2010; 
107:17280-5; PMID:20855626; http://dx.doi.
org/10.1073/pnas.1010263107.
25. Sabatos-Peyton CA, Verhagen J, Wraith DC. 
Antigen-specific immunotherapy of autoimmune and 
allergic diseases. Curr Opin Immunol 2010; 22:609-
15; PMID:20850958; http://dx.doi.org/10.1016/j.
coi.2010.08.006.
26. Peron JP, Yang K, Chen ML, Brandao WN, Basso AS, 
Commodaro AG, et al. Oral tolerance reduces Th17 
cells as well as the overall inflammation in the cen-
tral nervous system of EAE mice. J Neuroimmunol 
2010; 227:10-7; PMID:20580440; http://dx.doi.
org/10.1016/j.jneuroim.2010.06.002.
27. Song F, Guan Z, Gienapp IE, Shawler T, Benson J, 
Whitacre CC. The thymus plays a role in oral toler-
ance in experimental autoimmune encephalomyelitis. 
J Immunol 2006; 177:1500-9; PMID:16849456.
28. Hawiger D, Masilamani RF, Bettelli E, Kuchroo VK, 
Nussenzweig MC. Immunological unresponsiveness 
characterized by increased expression of CD5 on 
peripheral T cells induced by dendritic cells in vivo. 
Immunity 2004; 20:695-705; PMID:15189735; 
http://dx.doi.org/10.1016/j.immuni.2004.05.002.
29. Bynoe MS, Evans JT, Viret C, Janeway CA Jr. 
Epicutaneous immunization with autoantigenic 
peptides induces T suppressor cells that prevent 
experimental allergic encephalomyelitis. Immunity 
2003; 19:317-28; PMID:14499108; http://dx.doi.
org/10.1016/S1074-7613(03)00239-5.
30. Chastain EM, Miller SD. Molecular mimicry as 
an inducing trigger for CNS autoimmune demy-
elinating disease. Immunol Rev 2012; 245:227-38; 
PMID:22168423; http://dx.doi.org/10.1111/j.1600-
065X.2011.01076.x.
31. Kakalacheva K, Munz C, Lunemann JD. Viral trig-
gers of multiple sclerosis. Biochim Biophys Acta 2011; 
1812:132-40.
32. Lucas RM, Hughes AM, Lay ML, Ponsonby AL, 
Dwyer DE, Taylor BV, et al. Epstein-Barr virus and 
multiple sclerosis. J Neurol Neurosurg Psychiatry 
2011; 82:1142-8; PMID:21836034; http://dx.doi.
org/10.1136/jnnp-2011-300174.
33. Salvetti M, Giovannoni G, Aloisi F. Epstein-Barr 
virus and multiple sclerosis. Curr Opin Neurol 
2009; 22:201-6; PMID:19359987; http://dx.doi.
org/10.1097/WCO.0b013e32832b4c8d.
34. Kidd BA, Ho PP, Sharpe O, Zhao X, Tomooka 
BH, Kanter JL, et al. Epitope spreading to citrul-
linated antigens in mouse models of autoimmune 
arthritis and demyelination. Arthritis Res Ther 
2008; 10:R119; PMID:18826638; http://dx.doi.
org/10.1186/ar2523.
35. McMahon EJ, Bailey SL, Castenada CV, Waldner H, 
Miller SD. Epitope spreading initiates in the CNS 
in two mouse models of multiple sclerosis. Nat Med 
2005; 11:335-9; PMID:15735651; http://dx.doi.
org/10.1038/nm1202.
36. Ellmerich S, Mycko M, Takacs K, Waldner H, Wahid 
FN, Boyton RJ, et al. High incidence of spontaneous 
disease in an HLA-DR15 and TCR transgenic mul-
tiple sclerosis model. J Immunol 2005; 174:1938-46; 
PMID:15699121.
37. Schubert DA, Gordo S, Sabatino JJ Jr., Vardhana S, 
Gagnon E, Sethi DK, et al. Self-reactive human CD4 
T cell clones form unusual immunological synapses. 
J Exp Med 2012; 209:335-52; PMID:22312112; 
http://dx.doi.org/10.1084/jem.20111485.
38. Rosenthal KM, Edwards LJ, Sabatino JJ Jr., Hood 
JD, Wasserman HA, Zhu C, et al. Low 2-dimen-
sional CD4 T cell receptor affinity for myelin sets 
in motion delayed response kinetics. PLoS One 
2012; 7:e32562; PMID:22412888; http://dx.doi.
org/10.1371/journal.pone.0032562.
1038 Human Vaccines & Immunotherapeutics Volume 9 Issue 5
69. Madsen LS, Andersson EC, Jansson L, krogsgaard 
M, Andersen CB, Engberg J, et al. A humanized 
model for multiple sclerosis using HLA-DR2 and a 
human T-cell receptor. Nat Genet 1999; 23:343-7; 
PMID:10610182; http://dx.doi.org/10.1038/15525.2
68. Luckey D, Bastakoty D, Mangalam AK. Role of HLA 
class II genes in susceptibility and resistance to mul-
tiple sclerosis: studies using HLA transgenic mice. 
J Autoimmun 2011; 37:122-8; PMID:21632210; 
http://dx.doi.org/10.1016/j.jaut.2011.05.001.
66. McLaughlin KA, Chitnis T, Newcombe J, Franz B, 
Kennedy J, McArdel S, et al. Age-dependent B cell 
autoimmunity to a myelin surface antigen in pediat-
ric multiple sclerosis. J Immunol 2009; 183:4067-76; 
PMID:19687098; http://dx.doi.org/10.4049/jim-
munol.0801888.
67. Quandt JA, Huh J, Baig M, Yao K, Ito N, Bryant 
M, et al. Myelin basic protein-specific TCR/HLA-
DRB5*01:01 transgenic mice support the etiologic 
role of DRB5*01:01 in multiple sclerosis. J Immunol 
2012; 189:2897-908; PMID:22888134; http://
dx.doi.org/10.4049/jimmunol.1103087.
